Core Viewpoint - BD (Becton, Dickinson and Company) has officially launched the new BD FACSDi scover™ A8 imaging spectral flow cytometer series, which includes three-laser and four-laser configurations, complementing the previously released five-laser instruments, thereby providing more scientists with access to leading-edge technology in various fields such as immunology, cancer immunotherapy, and cell biology [1][2]. Group 1 - The BD FACSDi scover™ A8 series is equipped with BD SpectralFX™ technology, allowing scientists to analyze up to 50 or more features of individual cells with optimal resolution and sensitivity [2]. - The series also features BD CellView™ imaging technology, enabling high-speed imaging to reveal spatial and morphological information of cells, such as the location of proteins within individual cells, which can be visualized in real-time [2]. - All configurations of the BD FACSDi scover™ A8 series offer high throughput and unattended automation capabilities, optimizing cost-effectiveness through real-time imaging [3]. Group 2 - The intuitive software of the BD FACSDi scover™ A8 is designed for managing large datasets and is ready for standardized operation out of the box [3]. - The instruments can seamlessly integrate with the BD FACSDi scover™ S8 imaging spectral sorter and the BD reagent ecosystem, including the recently launched BD Horizon RealViolet™ 828 and RealBlue™ 824 fluorescent dyes, which are pioneering products in the near-infrared spectral range [3]. - Steve Conley, Global President of BD Biosciences, emphasized the importance of flexibility and modularity in acquiring cutting-edge technology in today's complex research environment, stating that the A8 series is rapidly adopted by leading biopharmaceutical companies and now offers more entry-level options for organizations of all sizes [3].